RXFP2

Across TCGA pan-cancer cohorts, RXFP2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RXFP2 data layer compared with 15 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher RXFP2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RXFP2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, UCEC, and DLBC are the cancer types where RXFP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.246	0.686	.004	21	view →
UCEC	DFS	Median	All	0.973	0.827	.014	14	view →
DLBC	OS	Median	All	0.053	0.936	<.001	12	view →
MESO	DFS	Median	All	0.099	0.392	.030	9	view →
LUAD	OS	Median	II,III,IV	0.228	0.559	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RXFP2–BLCA (OS)

Open the BLCA breakdown →